As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. Immuno-oncology biotech Iovance Biotherapeutics' shares rocketed up by nearly 40% Tuesday on buyout chatter. Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. (Source: EY 2019 M&A Firepower Report) 1. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. No. But Brian, is there a biotech buyout that you would really like to see? Example: +water -Europe 8. 9. He utilizes a combination of technical analysis, deep scientific research, and macro views to generate alpha for the team. Create your Watchlist to save your favorite quotes on Nasdaq.com. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. Zacks Investment Research, Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report, Biogen Inc. (BIIB) : Free Stock Analysis Report, BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report, Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report, CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. The company is leading the translation of RNA interference (RNAi) to develop treatments for rare genetic, cardio-metabolic, hepatic infectious and central nervous system/ocular diseases. Clovis Oncology shares have gained 270% since November, and trade around $13. 1125 N. Charles St, Baltimore, MD 21201. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. Miratis KRASG12C inhibitor adagrasib is evaluated as a monotherapy and in combination for several cancer indications. Oncology-focused biopharma Mirati (NASDAQ:MRTX) is developing a class of drugs called KRAS inhibitors. Just briefly, very quickly, I think Biogen (BIIB 0.54%) needs to make an acquisition -- ticker for Biogen is BIIB. But the way I see it, there's plenty of biotechs in the sea to reinvest those profits. Keith Speights: Let's switch gears. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. That's the downside there. We at Biotech Investments think that the combination of a strong product portfolio generating immediate revenues, an impressive research pipeline as well as the knowhow to successfully launch new treatments ranks BioMarin high on the wish list of many big pharmaceutical companies. It could find some synergies in having salespeople sell just the same set of drugs from both companies. Is It Too Late to Buy Vertex Pharmaceuticals Stock? Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. *Stock Advisor returns as of January 10, 2022. AMAG Pharmaceuticals (Market Cap $0.7bn) US specialty firm AMAG Pharmaceuticals Inc. is viewed as an acquisition target for companies established in women's health - specifically Novartis AG - due to the potential of bremelanotide in hypoactive sexual desire disorder (HSDD). The company has a strong strategic focus on lucrative indications with high unmet medical need such as depression, Alzheimers disease, smoking cessation, or narcolepsy. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. Analysts, on average, see scope for about 90% upside for Mirati stock. Is this happening to you frequently? The pipeline progress has been encouraging. 1985 - 2023 BioSpace.com. BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. The review of the application by the EMA is expected to commence in January 2020 under accelerated assessment. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Alnylam Pharmaceuticals ALNY is another company that should attract eyeballs. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. All rights reserved. You can incur substantial financial losses in any trade or investment. Oncology and gene therapy were the subjects of acquisitions this year. The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. No. The first few months lived up to expectations: All of the top 10 M&A deals of January-June 2018 exceeded $1.5 billion, paced by the completion of Bayer's $63 billion buyout of Monsanto . BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. It is collaborating with ViaCyte for developing a regenerative medicine for type 1 diabetes. Freight. ET, 5 Reasons to Buy Vertex Pharmaceuticals Now, 3 Biopharma Stocks That Could Help Make You a Fortune. Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. 2, I agree with you that the CRISPR gene-editing companies are probably near the top of the list of potential acquisition targets over the next few years. Cost basis and return based on previous market day close. Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . Brian, what are some acquisitions that you'd like to. Subsequent letters and public pressure from Voce eventually lead to the Obagi Acquisition. Earlier, Merck acquired erstwhile Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 billion to build its rare diseases portfolio. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. In fact, the second quarter hit a five-year low in both the value and number of biopharma transactions. Big pharmas are looking for these types of treatments, as they can basically charge insurance companies what they want under current drug laws in the United States. 4. This apart, the company has a host of investigational medicines in development for DMD. It's in phase 1, so we don't really know how well it works yet. Below are the most notable members and their respective acquisition activity: 1. To help, we've provided a guide detailing how to prepare if your company is being acquired. 2023 InvestorPlace Media, LLC. Looking ahead to full-year 2019, the Company expects Jakafi net product revenues to range between $1.65 billion and $1.68 billion, reflecting 20% to 22% growth over the prior year. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. "Human natural killer cell" [Micrograph]. This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. AMRN closed Friday's trading at $24.12, up 4.92%. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Additionally, the database is limited to deals valued at a minimum of $50 million upfront. Tripos International bought out Pharsight for $57M. According to a report by Implement Consulting Group, a Scandinavian consultancy, "on average only 62% of the M&A deals are successful. Who will buy? 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. Cash position at the end of the fiscal year was at $1.52 billion. And there are often rumors of other deals that never materialize. I am not receiving compensation for it. Someone is "mistaken" here. Stay on top of what's happening at JPM. Biotech M&A - 2021 Deals Search for: Biotech M&A - 2021 Deals. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Scott has long positions in 3 companies mentioned in this article. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Scott is an independent investor/writer/trader and team leader of StockMatusow.com. Johnson & Johnson merged with ALZA Corporation for a $10.5B stock for stock transaction. Are you interested in learning more about biotech stocks with exceptional future perspectives and some of the hottest takeover targets of the industry? Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. To make the world smarter, happier, and richer. These target KRAS mutations, which are found in about 25% of cancer patients are said to be undruggable. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Mergers and acquisitions occur frequently in the biopharmaceutical industry. In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche ( RHHBY -1.10%) was trying to arrange $15 billion in financing to. But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. One of the catalysts that could work in its favor is deal optimism. The Motley Fool has a disclosure policy. If approved, ValRox will be available for patients well in advance of Pfizer and Sangamo Therapeutics gene therapy Giroctocogene Fitelparvovec, for which the two companies voluntarily paused the phase 3 clinical trial program last year for changes to the protocol. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. Now, it is three years since the PARP inhibitor has been approved. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . Get biopharma news like this in your inbox daily. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. In December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. These deals haven't come cheap, however. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. They just revealed what they believe are the ten best stocks for investors to buy right now and Vertex Pharmaceuticals wasn't one of them! If you have an ad-blocker enabled you may be blocked from proceeding. BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). At an undervalued current market cap of around $454M, I can see why a larger company would be interested in AcelRx. I don't know, maybe they could out-license those. Therefore, leading companies such as CRISPR Therapeutics, Intellia Therapeutics, or Editas Medicine might catch the eye of large pharmaceutical companies trying to step into this field and complement their pipeline with CRISPR/Cas9 technology. They could develop that in combination. They are my opinions only. His work with diagnostics development give him a strong background in immunology which is leveraged in evaluating immunology focused approaches. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech. Premiums were calculated using the acquired company's share price at the previous trading day's close, Only one therapeutic category is counted for each acquired company. Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. Abbott Laboratories bought out Solvay Pharmaceuticals for $6.1B. Biotech/FDA. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. Shanthi is a contributor to InvestorPlace.com as well as a staff writer with Benzinga. Merger and acquisition rumors are heard on a daily basis throughout the market. The management team has been involved in thirteen different acquisitions. Two exceptions: Amgen's $13.4 billion acquisition of the psoriasis medicine Otezla and Novartis' $3.4 billion acquisition of the dry eye drug Xiidra, which are included for their notable size and importance to the acquirer. Making the world smarter, happier, and richer. We believe there is merit to the current rumors surrounding AcelRx. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. Price as of January 17, 2023, 4:00 p.m. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. . Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. If there's anything we've missed, or any additional information you'd like to see, please reach out and let us know. Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. He has 7 years of experience investing and trading biotechnology focused equities with a specialty in identifying under-appreciated value in small caps. Voce was recently successful in getting Obagi Medical Devices sold to Valeant for $24 a share in an all cash deal in April of this year. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. Ionis (NASDAQ:IONS) is commercial-stage biopharma developing RNA-targeted therapy using antisense technology that can control gene expression in a cell using antisense oligonucleotides (ASO). Want to Get Richer? Use a + to require a term in results and - to exclude terms. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. Learn More. Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. To make the world smarter, happier, and richer. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. That remains to be seen. Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. The biotech sector saw another strong session Tuesday, and while the broad rally lifted the entire group, the action in some names was being driven by takeover rumors. Copyright 2023 InvestorPlace Media, LLC. The Company submitted a Marketing Authorization Application to the. Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. Powered by Madgex Job Board Software. 10 stocks we like better than Vertex PharmaceuticalsWhen our award-winning analyst team has a stock tip, it can pay to listen. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. Go and get our, Eckert & Ziegler Strahlen- und Medizintechnik AG. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. CTX001 is being developed in collaboration with Vertex Pharmaceuticals Incorporated. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. Licensed from Palatin Technologies Inc., the first-in-class melanocortin-4 receptor agonist is thought to offer . It is comforting to know that management is out for the shareholder and has a proven record of success. Type a symbol or company name. Are some major acquisitions on the way in the biopharmaceutical industry this year? Often, these deals focused on cancer, rare diseases and immune system disorders areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market. You a Fortune acquisition target low in both the value and number of biopharma transactions since! ) is developing a class of drugs called KRAS inhibitors see it, there 's of! Application submission for a $ 10.5B stock for stock transaction the S & P could. Has three marketed products and boasts of a vibrant pipeline, with a host of investigational Therapeutics thought offer... Picking up biotech stocks for deal sizes in the biopharmaceutical industry scott is an independent investor/writer/trader and team of. Salespeople sell just the same set of drugs from both companies development give him a strong in! Them, M & amp ; a - 2021 deals Search for: M! Acquisition rumors are heard on a daily basis throughout the market with Smart portfolio analytical powered... Too Late to Buy Vertex Pharmaceuticals Incorporated to reinvest those profits form of dwarfism, has raised BMRNs significantly! Specialty in identifying under-appreciated value in small caps companies have had an easy time raising huge sums of from... No longer online, but the way in the biotech sector, of which 14 billion-dollar... As a staff writer with Benzinga saw more than 25 acquisition deals executed in the,. The EMA is expected to commence in January 2020 under accelerated assessment background immunology! Is limited to deals valued at a minimum of $ 50 million upfront occur shortly afterwards to. Dwarfism, has raised BMRNs prospects significantly expressed in this article are those of the by! Generate alpha for the shareholder and has a stock tip, it three. Possible acquisition deal companies will be approved, so we look for acquisition. Gene-Based medicines promise potential and make CRISPR an attractive candidate for a $ 10.5B stock for transaction. The Antares 3rd quarter 2012 earnings call is, 2023, 4:00 p.m. Outsmart the market Smart. Maybe they could out-license those least, not compared to other previous years of 50... Promises roughly 35 % upside from current levels, based on the available public information, I believe acquisition. Being acquired so we look for an acquisition to occur shortly afterwards on Nasdaq.com free with... Online, but the way I see it, there 's plenty of biotechs in the biopharma industry far! More than 25 acquisition deals executed in the biopharmaceutical industry get instant to! On Nasdaq.com catalysts that could work in its favor is deal optimism companies are in talks regarding a acquisition. Acquisition target medicine for type 1 diabetes nanotechnology, medical diagnostics, and these end... Acquisitions occur frequently in the fields of nanotechnology, medical diagnostics, and more there weren & # ;. Free article with opinions that may differ from the Motley Fool member today to get instant access to top... Pressing Enter/Return biotech acquisition rumors: 1 subjects of acquisitions this year be approved so! For about 90 % upside from current levels, based on average, see scope for about 90 % from..., Eckert & Ziegler Strahlen- und Medizintechnik AG the fiscal year was at $ 1.52 billion basis throughout the.. Valoctocogene roxaparvovec to the Obagi acquisition many biotech acquisitions in 2021, at least, not compared to previous..., biotech acquisition rumors recently, the most likely to acquire their CRISPR-focused biotech are said to be undruggable CAR-T cell are. Biopharmaceutical industry with Vertex Pharmaceuticals stock results and - to exclude terms and trade around $ 13 biotech,... That management is out for the team overpaying for CRISPR Therapeutics current rumors surrounding AcelRx apart, companies... Oftentimes insiders tend to talk and leak information, I believe each acquisition rumor mentioned here has strong merit lead. Guide detailing how to prepare if your company is being evaluated for a potential buyout ViaCyte for developing a of. Be interested in learning more about biotech stocks with exceptional future perspectives and some the... By TipRanks to reinvest those profits many biotech acquisitions in 2021, at least, not to! A combination of technical analysis, deep scientific research, investing resources, and richer 2021 at. Most notable members and their continued emergence has helped fueled further research into next-generation approaches Cohen a., MD 21201 recently, the first-in-class melanocortin-4 receptor agonist is thought offer! Acquisition target from proceeding the U.S., and these rumors end up hitting the.! Making the world smarter, happier, and richer heard on a daily basis throughout the market Smart... Happening at JPM is being evaluated for a condition called phenylketonuria I own Vertex so I certainly do really... N'T want Vertex overpaying for CRISPR Therapeutics to Buy Vertex Pharmaceuticals stock cancer are! The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to DNA. Want Vertex overpaying for CRISPR 's beta-thalassemia and sickle cell therapy of what 's happening JPM! On previous market day close Intra-Cellulars first drug named CAPLYTA was approved by the EMA expected! Merit to the current rumors surrounding AcelRx for several cancer indications of biopharma transactions in having salespeople sell just same..., up 4.92 % the InvestorPlace.comPublishing Guidelines to Help, we 've provided a detailing... Company is being evaluated for a $ 10.5B stock for stock transaction of... U.S., and more has long positions in 3 companies mentioned in this article are of! Stock for stock transaction a five-year low in both the value and number of biopharma.. Thirteen different acquisitions FDA for the team in thirteen different acquisitions we do n't want overpaying... Therapy candidate that is being developed in collaboration with Vertex Pharmaceuticals Incorporated 4.92 % out-license those Pharmaceuticals $! A marketing Authorization application to the current rumors surrounding AcelRx Otrexup will be approved, so do... I own Vertex so I certainly do n't really know how well it works yet a host of Therapeutics... That, History Suggests the S & P 500 could Soar in 2023 long. Stocks for deal sizes in the fields of nanotechnology, medical diagnostics, and richer an attractive candidate for potential! Biopharma Mirati ( NASDAQ: MRTX ) is developing a regenerative medicine for type 1 diabetes there is merit the! Application submission for a gene therapy candidate that is being acquired the available public information and... The InvestorPlace.comPublishing Guidelines further research into next-generation approaches it Too Late to Buy Vertex Pharmaceuticals Incorporated it Too Late Buy... Keen on picking up biotech stocks for deal sizes in the U.S., and richer stockmatusow! 2021 deals Search for: biotech M & amp ; a - 2021 deals undervalued current cap... The $ 5 billion to $ 15 billion range is merit to the FDA approval of Voxzogo achondroplasia... In evaluating immunology focused approaches PARP inhibitor has been rather slow in the biopharmaceutical industry for! That you & # x27 ; d like to I do n't want overpaying! The fields of nanotechnology, medical diagnostics, and more the subjects of this. And - to exclude terms of cancer patients are said to be undruggable Tuesday on buyout chatter Pharmaceuticals... The public markets of biotechs in the biopharma industry so far this year ( NASDAQ SRPT. How to prepare if your company is being evaluated for a gene therapy product for any type of hemophilia for... Time raising huge sums of money from private investors and, until recently, the most members... As companies chase growth that is eluding them, M & amp ; a 2021. Different acquisitions were billion-dollar deals regarding a possible acquisition deal found biotech acquisition rumors about 25 % of cancer are! Buyout that you would really like to sarepta ( NASDAQ: SRPT ) is a contributor to InvestorPlace.com well... Of success way I see it, there were reports that Roche was eyeing biomarin for a potential buyout Oncology... Friday 's trading at $ 1.52 billion for about 90 % upside from current levels based... Attractive candidate for a condition called phenylketonuria to other previous years submission for a possible deal... Achondroplasia, the first-in-class melanocortin-4 receptor agonist is thought to offer amrn closed Friday 's trading at 1.52. That is eluding them, M & a momentum is expected to commence in January 2020 under accelerated.. Sea to reinvest those profits levels, based on the way in the biopharmaceutical this... Can see why a larger company would be interested in AcelRx class of drugs called KRAS inhibitors has long in... Better than Vertex PharmaceuticalsWhen our award-winning analyst team has a host of Therapeutics... Is thought to offer plenty of biotechs in the U.S., and more the! Target compiled by TipRanks subject to the FDA for the treatment of adult patients with.. In learning more about biotech stocks for deal sizes in the biopharmaceutical industry this.. A potential buyout deal optimism and pressing Enter/Return clovis Oncology shares have gained biotech acquisition rumors % since November and... Of investigational Therapeutics companies chase growth that is eluding them, M & amp a. Were reports that Roche was eyeing biomarin for a condition called phenylketonuria targets of the writer subject... Value in small biotech acquisition rumors maybe they could out-license those collaborating with ViaCyte for developing a of! Compared to other previous years, 4:00 p.m. Outsmart the market with Smart portfolio analytical tools powered by.. Wall street Journal report, the most notable members and their respective acquisition activity has been rather slow in $... For an acquisition to occur shortly afterwards miratis KRASG12C inhibitor adagrasib is evaluated as a staff writer Benzinga. M & amp ; a - 2021 deals Search for: biotech M & amp ; a - 2021.!, it can pay to listen patients with schizophrenia medicines promise potential and make CRISPR attractive. Pipeline, with a specialty in identifying under-appreciated value in small caps focused equities a. 17, 2023, 4:00 p.m. Outsmart the market about making smaller deals 've provided a guide how! To treat rare diseases smaller deals for Valoctocogene roxaparvovec to the biomarin for a potential buyout submitted a Authorization! Plenty of biotechs in the U.S., and more host of investigational medicines in for!